| Dr John Claymon Heisey Jr, MD | |
|
4885 Demoss Rd, Suite 200, Reading, PA 19606-9023 | |
| (610) 779-0300 | |
| (610) 779-8083 |
| Full Name | Dr John Claymon Heisey Jr |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Location | 4885 Demoss Rd, Reading, Pennsylvania |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003830951 | NPI | - | NPPES |
| 000645838 | Medicaid | PA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | MD014667E (Pennsylvania) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr John Claymon Heisey Jr, MD 50 Commerce Dr, Wyomissing, PA 19610-3335 Ph: (610) 372-8044 | Dr John Claymon Heisey Jr, MD 4885 Demoss Rd, Suite 200, Reading, PA 19606-9023 Ph: (610) 779-0300 |
News Archive
U.S. Pharmacopeia (USP) Convention, an official public standards-setting authority for all prescription and over-the-counter medicines sold in the United States, on December 4, 2008 transferred all rights, ownership and management of the overall MEDMARX reporting program to Quantros.
Codman Neuro, part of DePuy Synthes Companies of Johnson & Johnson, announced regulatory approval from the China Food and Drug Administration, South Korea's Ministry of Food and Drug Safety, and the Taiwan Food and Drug Administration for the company's REVIVE SE Thrombectomy Device, a next-generation self-expanding clot removal device intended to restore blood flow in patients with acute ischemic stroke secondary to intracranial occlusive vessel disease.
An old, fickle therapy for a variety of autoimmune diseases is getting a makeover, thanks to a decade-long investigation by Rockefeller University researchers.
Scientists at the University of Southampton are continuing their pioneering research into diseases such as Creutzfeld-Jakob Disease (CJD) and related conditions caused by tiny particles known as prions, thanks to a £300,000 grant from the Medical Research Council.
GlaxoSmithKline and XenoPort, Inc. announced today that GSK has resubmitted the New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) requesting approval of Solzira(TM) (gabapentin enacarbil) Extended Release Tablets for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS).
› Verified 1 days ago
Nicole Baumgartner-fernandez, DO Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2500 Bernville Rd, Reading, PA 19605 Phone: 610-378-2000 Fax: 610-378-2799 | |
Elliott G Leisawitz, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 1020 Grings Hill Rd, Reading, PA 19608 Phone: 610-898-5030 Fax: 610-777-3474 | |
Amal George Kebede, DO Internal Medicine Medicare: Medicare Enrolled Practice Location: 2494 Bernville Road, Suite 205, Reading, PA 19605 Phone: 610-378-2996 Fax: 610-208-8812 | |
Dr. Vijay Singh, M,D, Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 3970 Perkiomen Ave, Suite 102, Reading, PA 19606 Phone: 610-779-1330 Fax: 610-779-7699 | |
Mary J. Bonner, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 1020 Grings Hill Rd, Reading, PA 19608 Phone: 610-898-5030 Fax: 610-777-3474 | |
Jacob D Pletz, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 2500 Bernville Rd, Reading, PA 19605 Phone: 610-378-2000 |